A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA

15339CO44668-MWHC-NCT05904886Open (affiliates only)A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMACO44668 (IMbrave152)NCT05904886IndustrialAdultTreatmentIIINationalOtherNoel, MarcusMedstar Washington Hospital Center : Shelley CollinsGastrointestinalOncology GroupMHRI Washington Cancer Institute13603Shelley CollinsShelley CollinsShelley.R.Collins@medstar.net2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>